This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jorgensen, J. H. Articles by Whitney, C. G. Search for Related Content PubMed PubMed Citation Articles by Jorgensen, J. H. Articles by Whitney, C. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2004, p. 605-607, Vol. 48, No. 2
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.2.605-607.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Activities of Cethromycin and Telithromycin against Recent North American Isolates of Streptococcus pneumoniae

Department of Pathology, University of Texas Health Science Center, San Antonio, Texas,¹ Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia²

Received 16 May 2003/ Returned for modification 1 September 2003/ Accepted 19 October 2003

The in vitro activities of two investigational ketolides, cethromycin (formerly ABT-773) and telithromycin, were determined for a selected group of 312 Streptococcus pneumoniae isolates from a national surveillance program. The MIC of cethromycin at which 50% of the isolates were inhibited was 0.008 µg/ml, and the MIC at which 90% of the isolates were inhibited was 0.06 µg/ml; the corresponding values for telithromycin were 0.015 and 0.25 µg/ml, respectively. For six quinupristin-dalfopristin-resistant strains, the cethromycin MICs were 0.25 to 16 µg/ml and the telithromycin MICs were 1 to 4 µg/ml. However, there was only 0.3% resistance to telithromycin.

This article has been cited by other articles:

• Azoulay-Dupuis, E., Mohler, J., Bedos, J. P., Barau, C., Fantin, B. (2006). Efficacy of Cethromycin, a New Ketolide, against Streptococcus pneumoniae Susceptible or Resistant to Erythromycin in a Murine Pneumonia Model.. Antimicrob. Agents Chemother. 50: 3033-3038 [Abstract] [Full Text]  
• Zhanel, G. G., Johanson, C., Laing, N., Hisanaga, T., Wierzbowski, A., Hoban, D. J. (2005). Pharmacodynamic Activity of Telithromycin at Simulated Clinically Achievable Free-Drug Concentrations in Serum and Epithelial Lining Fluid against Efflux (mefE)-Producing Macrolide- Resistant Streptococcus pneumoniae for Which Telithromycin MICs Vary. Antimicrob. Agents Chemother. 49: 1943-1948 [Abstract] [Full Text]  
• Kasbekar, N., Acharya, P. S. (2005). Telithromycin: The first ketolide for the treatment of respiratory infections. Am J Health Syst Pharm 62: 905-916 [Abstract] [Full Text]  
• Daly, M. M., Doktor, S., Flamm, R., Shortridge, D. (2004). Characterization and Prevalence of MefA, MefE, and the Associated msr(D) Gene in Streptococcus pneumoniae Clinical Isolates. J. Clin. Microbiol. 42: 3570-3574 [Abstract] [Full Text]